Literature DB >> 26937130

Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer.

Masakazu Yashiro1, Tasuku Matsuoka1.   

Abstract

Fibroblast growth factor receptors (FGFRs) regulate a variety of cellular functions, from embryogenesis to adult tissue homeostasis. FGFR signaling also plays significant roles in the proliferation, invasion, and survival of several types of tumor cells. FGFR-induced alterations, including gene amplification, chromosomal translocation, and mutations, have been shown to be associated with the tumor initiation and progression of gastric cancer, especially in diffuse-type cancers. Therefore, the FGFR signaling pathway might be one of the therapeutic targets in gastric cancer. This review aims to provide an overview of the role of FGFR signaling in tumorigenesis, tumor progression, proliferation, and chemoresistance. We also discuss the accumulating evidence that demonstrates the effectiveness of using clinical therapeutic agents to inhibit FGFR signaling for the treatment of gastric cancer.

Entities:  

Keywords:  Fibroblast growth factor receptor; Gastric cancer; Signaling pathway; Targeted therapy

Mesh:

Substances:

Year:  2016        PMID: 26937130      PMCID: PMC4768188          DOI: 10.3748/wjg.v22.i8.2415

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  61 in total

Review 1.  Cell signaling by receptor tyrosine kinases.

Authors:  J Schlessinger
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

Review 2.  FGF receptor inhibitors: role in cancer therapy.

Authors:  Gennaro Daniele; Jesus Corral; L Rhoda Molife; Johann S de Bono
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

Review 3.  Current status of novel agents in advanced gastroesophageal adenocarcinoma.

Authors:  Nishi Kothari; Khaldoun Almhanna
Journal:  J Gastrointest Oncol       Date:  2015-02

4.  Twist1 correlates with poor differentiation and progression in gastric adenocarcinoma via elevation of FGFR2 expression.

Authors:  Dong-Yuan Zhu; Qi-Sen Guo; Yan-Liang Li; Bin Cui; Jun Guo; Ji-Xiao Liu; Peng Li
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

Review 5.  Targeting mutant fibroblast growth factor receptors in cancer.

Authors:  Heidi Greulich; Pamela M Pollock
Journal:  Trends Mol Med       Date:  2011-03-01       Impact factor: 11.951

6.  siRNA-participated chemotherapy: an efficient and specific therapeutic against gastric cancer.

Authors:  Donglei Zhou; Xun Jiang; Weixing Ding; Lijun Zheng; Lei Yang; Chengzhu Zheng; Liesheng Lu
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-28       Impact factor: 4.553

7.  Keratinocyte growth factor regulates proliferation and differentiation of hematopoietic cells expressing the receptor gene K-sam.

Authors:  Tamihiro Kamata; Yutaka Hattori; Hirofumi Hamada; Masahiro Kizaki; Masaaki Terada; Yasuo Ikeda
Journal:  Exp Hematol       Date:  2002-04       Impact factor: 3.084

8.  Co-expression of keratinocyte growth factor and K-sam is an independent prognostic factor in gastric carcinoma.

Authors:  Takahiro Toyokawa; Masakazu Yashiro; Kosei Hirakawa
Journal:  Oncol Rep       Date:  2009-04       Impact factor: 3.906

Review 9.  Dysregulation of stem cell signaling network due to germline mutation, SNP, Helicobacter pylori infection, epigenetic change and genetic alteration in gastric cancer.

Authors:  Masaru Katoh
Journal:  Cancer Biol Ther       Date:  2007-03-26       Impact factor: 4.742

10.  Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer.

Authors:  Lincoln D Nadauld; Sarah Garcia; Georges Natsoulis; John M Bell; Laura Miotke; Erik S Hopmans; Hua Xu; Reetesh K Pai; Curt Palm; John F Regan; Hao Chen; Patrick Flaherty; Akifumi Ootani; Nancy R Zhang; James M Ford; Calvin J Kuo; Hanlee P Ji
Journal:  Genome Biol       Date:  2014-08-27       Impact factor: 17.906

View more
  11 in total

1.  Targeted FGFR/VEGFR/PDGFR inhibition with dovitinib enhances the effects of nab-paclitaxel in preclinical gastric cancer models.

Authors:  Kate Crawford; Erin Bontrager; Margaret A Schwarz; Apurva Chaturvedi; Daniel D Lee; Hassan Md Sazzad; Urs von Holzen; Changhua Zhang; Roderich E Schwarz; Niranjan Awasthi
Journal:  Cancer Biol Ther       Date:  2021-12-09       Impact factor: 4.742

Review 2.  Role of tumor microenvironment in tumorigenesis.

Authors:  Maonan Wang; Jingzhou Zhao; Lishen Zhang; Fang Wei; Yu Lian; Yingfeng Wu; Zhaojian Gong; Shanshan Zhang; Jianda Zhou; Ke Cao; Xiayu Li; Wei Xiong; Guiyuan Li; Zhaoyang Zeng; Can Guo
Journal:  J Cancer       Date:  2017-02-25       Impact factor: 4.207

3.  Differential Expression of FGFRs Signaling Pathway Components in Bladder Cancer: A Step Toward Personalized Medicine.

Authors:  Ousati Ashtiani Z; Tavakkoly-Bazzaz J; Salami Sa; Pourmand Mr; Mansouri F; Mashahdi R; Pourmand G
Journal:  Balkan J Med Genet       Date:  2017-12-29       Impact factor: 0.519

Review 4.  What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives.

Authors:  Giuseppe Tirino; Luca Pompella; Angelica Petrillo; Maria Maddalena Laterza; Annalisa Pappalardo; Marianna Caterino; Michele Orditura; Fortunato Ciardiello; Gennaro Galizia; Ferdinando De Vita
Journal:  Int J Mol Sci       Date:  2018-09-07       Impact factor: 5.923

5.  Anti-fibrotic properties of an adiponectin paralog protein, C1q/TNF-related protein 6 (CTRP6), in diffuse gastric adenocarcinoma.

Authors:  Yoshinori Iwata; Itaru Yasufuku; Chiemi Saigo; Yusuke Kito; Tamotsu Takeuchi; Kazuhiro Yoshida
Journal:  J Cancer       Date:  2021-01-01       Impact factor: 4.207

6.  Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer.

Authors:  Masakazu Yashiro; Kenji Kuroda; Go Masuda; Tomohisa Okuno; Yuichiro Miki; Yurie Yamamoto; Tomohiro Sera; Atsushi Sugimoto; Shuhei Kushiyama; Sadaaki Nishimura; Shingo Togano; Masaichi Ohira
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379

Review 7.  Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer.

Authors:  Navid Sobhani; Anna Ianza; Alberto D'Angelo; Giandomenico Roviello; Fabiola Giudici; Marina Bortul; Fabrizio Zanconati; Cristina Bottin; Daniele Generali
Journal:  Cells       Date:  2018-07-15       Impact factor: 6.600

Review 8.  Biomarkers of gastric cancer: Current topics and future perspective.

Authors:  Tasuku Matsuoka; Masakazu Yashiro
Journal:  World J Gastroenterol       Date:  2018-07-14       Impact factor: 5.742

Review 9.  The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments.

Authors:  Sobhani Navid; Chunmei Fan; Pedro O Flores-Villanueva; Daniele Generali; Yong Li
Journal:  Int J Mol Sci       Date:  2020-03-16       Impact factor: 5.923

Review 10.  Issues of origin, morphology and clinical significance of tumor microvessels in gastric cancer.

Authors:  Marina A Senchukova
Journal:  World J Gastroenterol       Date:  2021-12-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.